(2) Events reportable by each entity are as
follows:
(a) acute flaccid myelitis;
(b) adverse event resulting from smallpox
vaccination (vaccinia virus, orthopox virus);
(c) anaplasmosis (Anaplasma
phagocytophilum);
(d) anthrax
(Bacillus anthracis) or anthrax-like illness caused by Bacillus cereus strains
that express anthrax toxin genes;
(e) antibiotic resistant organisms from any
clinical specimen that meet the following criteria:
(i) resistant to a carbapenem in:
(A) Acinetobacter species;
(B) Enterobacter species;
(C) Escherichia coli; or
(D) Klebsiella species; or
(ii) Resistant to vancomycin in
Staphylococcus aureus (VRSA); or
(iii) demonstrated carbapenemase production
in:
(A) Acinetobacter species;
(B) Enterobacter species;
(C) Escherichia coli;
(D) Klebsiella species; or
(E) any other Enterobacteriaceae
species;
(f)
arbovirus infection, including:
(i)
chikungunya virus infection;
(ii)
West Nile virus infection; and
(iii) Zika virus infection; including
congenital;
(g)
babesiosis (Babesia spp.);
(h)
botulism (Clostridium botulinum);
(i) brucellosis (Brucella spp.);
(j) campylobacteriosis (Campylobacter
spp.);
(k) Candida auris or Candida
haemulonii from any body site;
(I)
Chagas disease (Trypanosoma cruzi);
(m)
chancroid (Haemophilus ducreyi);
(n) chickenpox (varicella zoster virus, VZV,
human herpesvirus 3, HHV-3);
(o)
chlamydia (Chlamydia trachomatis);
(p) coccidioidomycosis (Coccidioides spp.),
also known as valley fever;
(q)
Colorado tick fever (Colorado tick fever virus, Coltivirus spp.), also known as
American mountain tick fever;
(r)
novel coronavirus disease including Middle East respiratory syndrome
(MERS-CoV), and Severe acute respiratory syndrome (SARS-CoV);
(s) COVID-19 (SARS-CoV-2);
(t) cryptosporidiosis (Cryptosporidium
spp.);
(u) cyclosporiasis
(Cyclospora spp., including Cyclospora cayetanensis);
(v) dengue fever (dengue virus);
(w) diphtheria (Corynebacterium
diphtheriae);
(x) ehrlichiosis
(Ehrlichia spp.);
(y) encephalitis
(bacterial, fungal, parasitic, protozoan, and viral);
(z) Shiga toxin-producing Escherichia coli
(STEC) infection;
(aa) giardiasis
(Giardia lamblia), also known as beaver fever;
(bb) gonorrhea (Neisseria gonorrhoeae),
including sexually transmitted and ophthalmia neonatorum;
(cc) Haemophilus influenzae, invasive
disease;
(dd) hantavirus infection
(Sin Nombre virus);
(ee) hemolytic
uremic syndrome, postdiarrheal;
(ff) hepatitis, viral including:
(i) hepatitis A;
(ii) hepatitis B (acute, chronic, and
perinatal);
(iii) hepatitis C
(acute, chronic, and perinatal);
(iv) hepatitis D; and
(v) hepatitis E;
(gg) human immunodeficiency virus (HIV)
infection, including acquired immune deficiency syndrome (AIDS);
(hh) influenza virus infection:
(i) associated with a
hospitalization;
(ii) associated
with a death in a person under 18 years of age; or
(iii) suspected or confirmed to be caused by
a non-seasonal influenza strain;
(ii) Legionellosis (Legionella spp.), also
known as Legionnaires' disease;
(jj) leptospirosis (Leptospira
spp.);
(kk) listeriosis (Listeria
spp., including Listeria monocytogenes);
(II) Lyme disease (Borrelia burgdorferi,
Borrelia mayonii);
(mm) malaria
(Plasmodium spp.);
(nn) measles
(measles virus), also known as rubeola;
(oo) meningitis (bacterial, fungal,
parasitic, protozoan, and viral);
(pp) meningococcal disease (Neisseria
meningitidis), invasive;
(qq) mumps
(mumps virus);
(rr) mycobacterial
infections, including:
(i) tuberculosis
(Mycobacterium tuberculosis complex);
(ii) leprosy (Mycobacterium leprae), also
known as Hansen's disease; or
(iii)
any other mycobacterial infections (Mycobacterium spp.);
(ss) pertussis (Bordetella
pertussis);
(tt) plague (Yersinia
pestis);
(uu) poliomyelitis
(poliovirus), paralytic and nonparalytic;
(vv) psittacosis (Chlamydophila psittaci),
also known as ornithosis;
(ww) Q
fever (Coxiella burnetii);
(xx)
rabies (rabies virus), human and animal;
(yy) relapsing fever (Borrelia spp.),
tick-borne and louse-borne;
(zz)
rubella (rubella virus), including congenital syndrome;
(aaa) salmonellosis (Salmonella
spp.);
(bbb) shigellosis (Shigella
spp.);
(ccc) smallpox (Variola
major and Variola minor);
(ddd)
spotted fever rickettsioses (Rickettsia spp.), including Rocky Mountain spotted
fever (Rickettsia rickettsii);
(eee) streptococcal disease, invasive, due
to:
(i) Streptococcus pneumoniae;
(ii) group A streptococcus (Streptococcus
pyogenes); or
(iii) group B
streptococcus (Streptococcus agalactiae);
(fff) Syphilis (Treponema pallidum),
including:
(i) any stage;
(ii) congenital; and
(iii) syphilitic stillbirths;
(ggg) tetanus (Clostridium
tetani);
(hhh) toxic shock
syndrome, staphylococcal (Staphylococcus aureus) or streptococcal
(Streptococcus pyogenes);
(iii)
transmissible spongiform encephalopathies (prion diseases), including
Creutzfeldt-Jakob disease;
(jjj)
trichinellosis (Trichinella spp.);
(kkk) tularemia (Francisella
tularensis);
(lll) typhoid
(Salmonella typhi), cases and carriers;
(mmm) vibriosis (Vibrio spp.), including
cholera (Vibrio cholerae);
(nnn)
viral hemorrhagic fevers including:
(i) Ebola
virus disease (Ebolavirus spp.);
(ii) Lassa fever (Lassa virus); and
(iii) Marburg fever (Marburg
virus);
(ooo) yellow
fever (yellow fever virus).
(4) Antimicrobial susceptibility
tests reportable by each entity are as follows:
(a) Full panel antimicrobial susceptibility
test results, including minimum inhibitory concentration and results suppressed
to the ordering clinician, are reportable when performed on the following
organisms:
(i) Candida auris or Candida
haemulonii from any body site;
(ii)
Mycobacterium tuberculosis;
(iii)
Neisseria gonorrhoeae;
(iv)
Salmonella species;
(v) Shigella
species; and
(vi) Streptococcus
pneumoniae;
(vii) organisms
resistant to a carbapenem in:
(A)
Acinetobacter species;
(B)
Enterobacter species;
(C)
Escherichia coli; or
(D) Klebsiella
species;
(viii) organisms
resistant to vancomycin in Staphylococcus aureus (VRSA).
(b) Individual carbapenemase test results
including positive, negative, equivocal, indeterminate and the method used, are
reportable when performed on organisms resistant to a carbapenem, or with
demonstrated carbapenemase, in:
(i)
Acinetobacter species;
(ii)
Enterobacter species;
(iii)
Escherichia coli; and
(iv)
Klebsiella species.
(c)
Antiviral susceptibility test results, including nucleotide sequencing,
genotyping, or phenotypic analysis, are reportable when performed on:human
immunodeficiency virus (HIV).
(7) Laboratory
results reportable by electronic reporters are as follows:
(a) In addition to laboratory results set
forth in Subsections R386-702-3(2)
through R386-702-3(6),
entities reporting electronically shall include the following laboratory
results or laboratory results that provide presumptive evidence of the
following communicable diseases:
(i) influenza
virus;
(ii) norovirus
infection;
(iii) Pseudomonas
aeruginosa, resistant to a carbapenem, or with demonstrated carbapenemase
production;
(iv) Staphylococcus
aureus from a normally sterile site with methicillin testing performed,
reported as either methicillin-susceptible Staphylococcus aureus (MSSA) or
methicillin-resistant Staphylococcus aureus (MRSA); and
(v) Streptococcal disease, invasive due to
all species.
(b) Entities
reporting electronically shall include any laboratory results including
positive, negative, equivocal, indeterminate, associated with the following
tests or conditions:
(i) CD4+ T-Lymphocyte
tests, regardless of known HIV status;
(ii) chlamydia;
(iii) Clostridium difficile;
(iv) novel coronavirus COVID-19 (SARS-CoV-2),
detected by a SARS-CoV-2 NAAT;
(v)
cytomegalovirus (CMV), congenital (infants less than or equal to 12 months of
age);
(vi) gonorrhea;
(vii) hepatitis A;
(viii) hepatitis B, including viral
loads;
(ix) hepatitis C, including
viral loads;
(x) HIV, including
viral loads and confirmatory tests;
(xi) liver function tests, including ALT,
AST, and bilirubin associated with a viral hepatitis case;
(xii) Lyme disease;
(xiii) respiratory syncytial virus
(RSV);
(xiv) syphilis;
(xv) tuberculosis; and
(xvi) Zika virus.
(c) Entities reporting electronically shall
report full panel antibiotic susceptibility test results, including minimum
inhibitory concentration and results suppressed to the ordering clinician, are
reportable when performed on Pseudomonas aeruginosa, resistant to a carbapenem,
or with demonstrated carbapenemase.
(d) The Department may, by authority granted
through Title 26B, Chapter 7, Part 2, Detection and Management of Chronic and
Communicable Diseases and Public Health Emergencies, identify additional
reporting criteria when deemed necessary for the management of outbreaks or
identification of exposures.
(e)
Non-positive laboratory results reported for the events identified in
Subsection R386-702-3(7)(b)
will be used for the following purposes:
(i)
to determine when a previously reported case becomes non-infectious;
(ii) to identify newly acquired infections
through identification of a seroconversion window; or
(iii) to provide information critical for
assignment of a case status.
(f) Information associated with a
non-positive laboratory result will be kept by the Department for a period of
18 months.
(i) At the end of the 18 month
period, if the result has not been appended to an existing case, personal
identifiers will be stripped and expunged from the result.
(ii) The de-identified result will be added
to a de-identified, aggregate data set.
(iii) The data set will be kept for use by
public health to analyze trends associated with testing patterns and case
distribution, and identify and establish prevention and intervention efforts
for at-risk populations.
(8) Authorized reporting of syndromes and
conditions are as follows:
(a) Reporting of
encounters for the following syndromes and conditions is authorized by Sections
26B-7-202,
26B-7-206, and
26B-7-207, unless made mandatory
by the declaration of a public health emergency:
(i) respiratory illness, including:
(A) upper or lower respiratory tract
infections;
(B) difficulty
breathing; or
(C) adult respiratory
distress syndrome;
(ii)
gastrointestinal illness, including:
(A)
vomiting;
(B) diarrhea;
or
(C) abdominal pain;
(iii) influenza-like
constitutional symptoms or signs;
(iv) neurologic symptoms or signs indicating
the possibility of meningitis, encephalitis, or unexplained acute
encephalopathy or delirium;
(v)
rash illness;
(vi) hemorrhagic
illness;
(vii) botulism-like
syndrome;
(viii)
lymphadenitis;
(ix) sepsis or
unexplained shock;
(x) febrile
illness (illness with fever, chills or rigors);
(xi) nontraumatic coma or sudden death;
and
(xii) other criteria specified
by the Department as indicative of disease outbreaks or injurious exposures of
uncertain origin.
(b)
Reporting of encounters for syndromes and conditions not specified in
Subsection R386-702-3(8)(a)
is also authorized by Sections
26B-7-316 through
26B-7-324, unless made mandatory
by the declaration of a public health emergency.
(c) Information included in the reporting of
the events identified in Subsections
R386-702-3(8)(a)
and R386-702-3(8)(b)
will be used for the following purposes:
(i)
to support early identification and ruling out of public health threats,
disasters, outbreaks, suspected incidents, and acts of bioterrorism;
(ii) to assist in characterizing population
groups at greatest risk for disease or injury;
(iii) to support assessment of the severity
and magnitude of possible threats; or
(iv) to satisfy syndromic surveillance
objectives of the Federal Centers for Medicaid and Medicare Meaningful Use
incentive program.
(9) Reporting exceptions:
(a) A university or hospital that conducts
research studies exempt from reporting AIDS and HIV infection under Section
26B-7-203 shall seek written
approval of reporting exemption from the Department institutional review board
before the study commencement.
(b)
The university or hospital shall submit the following to the HIV Epidemiologist
within 30 days of Department institutional review board approval:
(i) a summary of the research protocol,
including funding sources and justification for requiring anonymity;
and
(ii) written approval from the
Department institutional review board.
(c) The university or hospital shall submit a
report that includes each of the indicators specified in Subsection
26B-7-203(4)(a)
to the HIV Epidemiologist annually during an ongoing research study.
(d) The university or hospital shall submit a
final report that includes each of the indicators specified in Subsection
26B-7-203(4)(a)
to the HIV Epidemiologist within 30 days of the conclusion of the research
study.
(e) Documents can be
submitted to the HIV Epidemiologist by fax at (801) 538-9923 or by mail to 288
North 1460 West Salt Lake City, Utah 84116.